ABSTRACT

The current research targeted the development of oral thin film of curcumin. Parkinson's disease (PD) is the second-most prevalent neurodegenerative condition that affects 2-3% of individuals > 65 years. Oral thin film has been termed as an alternative route to traditional dosage form. They are a platform that offer rapid, local or systemic action. The key objective of this is to allow for rapid onset of action, enhanced bioavailability and to make administration more convenient to the patient. Curcumin is a polyphenolic extract from the rhizomes of Curcuma longa (turmeric). It has been shown to exhibit strong anti-inflammatory, antioxidant, mitochondrial protective effects and is thought to be a potential therapeutic and nutraceutical agent in treating PD. The dissolution rate can be enhanced by HPMC as a polymer and glycerine as a plasticizer through solvent casting technique. Ashwagandha is incorporated in formulation possess neuroprotective property and utilized in the treatment of PD. The film was tested for their physiochemical parameter such as disintegration time, surface pH, thickness, weight, percent moisture absorption, folding endurance, drug content and stability testing. Curcumin has low bioavailability but formulation with piperine (black pepper) is employed to facilitate absorption. Curcumin possesses neuroprotective property and has the ability to cross the blood brain barrier, hence it aids in the treatment of Parkinson disease. Keywords: Curcumin, Parkinson’s disease, Neuroprotection, Oral thin film
Publication date: 01/07/2026

https://www.ijbpas.com/pdf/2026/July/MS_IJBPAS_2026_10116.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.7.10116